Chicago -’ Tempus AI, Inc. (NASDAQ: TEM), a technology company at the forefront of artificial intelligence and precision medicine, continues to set new benchmarks in the healthcare sector. In a significant stride forward, the company recently announced that four of its abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024. This influential event will be held in Barcelona, Spain, from September 13-17, 2024.
The ESMO Congress, known for its role as a global hub for oncology professionals, will provide Tempus with an invaluable platform to share the latest research and developments. Eric Lefkofsky, Founder and CEO of Tempus, expressed enthusiasm over this opportunity, stating, ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive progress in precision medicine.
This announcement comes on the heels of Tempus achieving another remarkable milestone surpassing 500 research publications. Over the past eight years, the company has engaged in extensive scientific research to authenticate its diagnostic tools and collaborate with biopharmaceutical entities and academic institutions. These collaborations have leveraged Tempus’ multimodal data library, leading to significant advancements and validated outcomes in precision medicine.
Tempus’ dedication to innovation and scientific rigor doesn’t stop there. The company’s revolutionary PurISTSM algorithmic test recently received a Proprietary Laboratory Analysis (PLA) code from the American Medical Association (AMA). Effective October 1, 2024, this code is the first of its kind to describe an algorithm-only analysis from previously sequenced, laboratory-developed data. This recognition underscores the impact and reliability of Tempus’ data-driven approaches.
The PurISTSM test represents a cutting-edge shift in patient care. It exemplifies how Tempus leverages artificial intelligence to generate precise diagnostic insights, which can have a profound influence on treatment paradigms and outcomes.
By securing a prominent presence at ESMO 2024, celebrating an immense body of published research, and earning AMA recognition for its innovative diagnostic test, Tempus AI reiterates its leadership in the field. The company’s ongoing commitment to scientific excellence and collaboration promises to accelerate the adoption of precision medicine, ensuring better patient care and outcomes on a global scale.
As the healthcare landscape continues to evolve, Tempus remains a beacon of innovation, harnessing the power of artificial intelligence to push the frontiers of medical science. The future looks promising as they persist in their mission to improve patient lives through groundbreaking technological advancements.
Comments